“Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge”

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 6, 2016, Pages 589-593

  Andrade, Raúl J ^a,b   Ortega Alonso, Aida ^a   Lucena, María Isabel ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETAHISTINE; BILIRUBIN; CHLORPHENIRAMINE; FLUCLOXACILLIN; HLA ANTIGEN; MACROLIDE; METOCLOPRAMIDE; TETRACYCLINE DERIVATIVE;

ACUTE LIVER FAILURE; BILIRUBIN BLOOD LEVEL; DIETARY SUPPLEMENT; EDITORIAL; FULMINANT HEPATIC FAILURE; GENETIC BACKGROUND; GENETIC SUSCEPTIBILITY; HUMAN; LIVER TOXICITY; TOXIC HEPATITIS; ANIMAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HEALTH; PRECLINICAL STUDY; PROCEDURES; TOXICITY TESTING;

ANIMALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLOBAL HEALTH; HUMANS; TOXICITY TESTS;

EID: 84958047781     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1141896     Document Type: Editorial

References (19)

1. P.B.Watkins, P.J.Seligman, J.S.Pears, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48:1680–1689.
2. M.Chen, A.Suzuki, J.Borlak, et al. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63:503–514.• An updated overview on the necessary and complex interplay among several host-dependent factors and the chemical structures of drugs to produce drug-induced liver injury (DILI).
3. F.J.De Abajo, D.Montero, M.Madurga, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58:71–80.
4. http://livertox.nih.gov/. Accessed 19November 2015.
5. C.Sgro, F.Clinard, K.Ouazir, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455.
6. E.S.Bjornsson, O.M.Bergmann, H.K.Bjornsson, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.• The first population-based study to provide reliable data on DILI incidence and the population exposed enabling for specific figures of hepatotoxicity related to individual drugs.
7. D.S.Goldberg, K.A.Forde, D.M.Carbonari, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology. 2015;148:1353–1361.
8. L.Dara, Z.Liu, N.Kaplowitz, Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2015; [Oct20]. doi:10.1111/liv.12988.• A review of the potential factors involved in the adaptation versus progression of the lesion induced by chemical agents on the liver and the fundamental role of the adaptive immune system on this balance.
9. R.J.Andrade, M.I.Lucena, M.C.Fernández, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–521.•• The pioneering Spanish Registry on hepatotoxicity provided consistent data on the drugs most commonly involved in DILI as well as the risk factors for drug-induced fulminant liver failure.
10. F.Bessone, N.Hernández, A.Sánchez, et al. A comparative analysis of the Spanish and Latin-American prospective drug-induced liver injury (DILI) networks. Hepatology. 2015;62:504A.
11. N.Chalasani, H.L.Bonkovsky, R.Fontana, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340–1352.• An update of the US-based DILI database that reported the worse prognosis and greater mortality of DILI patients with preexisting liver disease.
12. Spanish DILI Registry. Málaga (Spain). [cited 2015 Nov 21]. Available from: www.spanishdili.uma.es
13. Spanish Latin American DILI Network. [cited 2015 Nov 21]. Available from: www.slatindili.uma.es
14. Drug-Induced Liver Injury Network. Bethesda (MD): The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). [cited 2015 Nov21]. Available from: http://www.dilin.org/
15. M.Robles-Diaz, M.I.Lucena, N.Kaplowitz, et al. Use of Hy’s Law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147:109–118.• Statistical analysis of the Spanish and Latin American DILI databases enabled to develop and test new models for predicting acute liver failure based on liver biochemistry at onset of hepatotoxicity.
16. M.I.Lucena, R.J.Andrade, N.Kaplowitz, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49:2001–2009.
17. C.Stephens, R.J.Andrade, M.I.Lucena Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;14:286–292.
18. G.P.Aithal. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Intern. 2015;35:1801–1808.
19. R.Teschke, R.J.Andrade. Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology. 2015;148:1271–1273.